Travere therapeutics to present abstracts at the society for inherited metabolic disorders 44th annual meeting and the american college of medical genetics and genomics annual clinical genetics meeting 2023

San diego, march 14, 2023 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced that the company will present a quantitative systems pharmacology (qsp) model for predicting the effects of the investigational enzyme replacement therapy pegtibatinase, in classical homocystinuria (hcu), as well as real-world evidence on the prevalence and potential underdiagnosis and/or underreporting of hcu in the united states, at the 2023 society for inherited metabolic disorders (simd) 44th annual meeting in salt lake city, ut, march 18-21, 2023. the company and its collaborators will also provide presentations from the company's ongoing longitudinal natural history study of people living with hcu, and hcu incidence estimates based on gnomad database evaluation at the american college of medical genetics and genomics (acmg) annual clinical genetics meeting in salt lake city, ut, march 14-18, 2023.
TVTX Ratings Summary
TVTX Quant Ranking